Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Despite its status as the “pharmacy of the world,” India’s deep life sciences roots have traditionally been based in manufacturing and replication. | A string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.
Indian pharma majors are advancing 10+ novel assets, with AbbVie paying $700M to Glenmark for a myeloma antibody. The shift from generics to discovery shows $40-50B firms now fund biotech; early wins reshape global pharma competition and India's ecosystem.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Private equity and venture capital investment in pharma rose 2.1x in five years to $ 731 million for the year ended March 2026,…

India sets its sights on becoming a frontrunner in innovation within the life sciences arena. The Bharat Life Sciences Award 2026…

India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global…

This article is authored by Uma Sinha Datta and Goutam Bhattacharya.

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars,…

While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…